Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 290 clinical trials
Program_Formal_v6.14.formal1  

Acne usually begins in the teenage years and disappears after eight to 10 years. In some cases, it can persist until the 30s and even 40s. Acne is caused by inflammation of the hair follicles. It most commonly affects the face, back and chest. Features include blackheads, whiteheads, pimples (zits) …

  • 0 views
  • 09 Feb, 2025
Featured trial
AutoRun129  

AutomationRun129

  • 0 views
  • 19 Feb, 2024
Featured trial
  • 0 views
  • 09 Aug, 2024
  • 1 location
Featured trial
v6.11_prescreener_study(please don't touch)

Intense stress has harmful effects on the body, contributing to various disorders. Breast cancer patients experience a build-up of stress due to their diagnosis and treatments. Stress can cause epigenetic changes in a cellular level (such as accelerated increase in biological age) that may negatively affect oncological treatments.This study aims …

Accepts healthy volunteers
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …

advanced breast cancer
estrogen receptor
estrogen receptor positive breast cancer
er-positive breast cancer
oestrogen receptor positive breast cancer
  • 0 views
  • 19 Feb, 2024
  • 126 locations
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom  

The primary objective of the study is to demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, W, and Y in terms of hSBA vaccine seroprotection (antibody titer ≥ 1:8) when MenACYW conjugate vaccine is administered concomitantly with Bexsero® in the second year of life compared to …

Accepts healthy volunteers
  • 0 views
  • 19 Feb, 2024
  • 12 locations
  • None views
  • None views
  • None views
  • None views